Vivtex Enters Research Collaboration with Astellas Pharma
23 Jan 2024
License out/in
Cambridge, MA, USA and Zurich, Switzerland – 23rd January 2024. Vivtex Corporation (“Vivtex” or “the Company”), a biotech company aiming to transform the development of oral biologic therapies for major diseases, announces that it has entered a research collaboration with Astellas Pharma US, Inc. (“Astellas”), a global pharmaceutical company. The collaboration is focused on the evaluation of Vivtex’s unique and proprietary GI-ORIS™ (“Gut on a chip” and AI) screening and formulation platform technology to support the development of novel, oral versions of a therapeutic candidate provided by Astellas.
Maureen Deehan, CEO of Vivtex, commented: “We are delighted to enter this new collaboration with Astellas Pharma. Over the past few years, Vivtex has worked productively with multiple leading pharma and biotech companies to apply its GI-ORIS™ platform to the challenge of improving drug oral bioavailability and thereby creating valuable new product opportunities and potential benefits to patients.”
Vivtex scientists demonstrated the ability and potential of the GI-ORIS™ platform to expedite the development of new orally available biologic drugs in a 2020 study published in Nature Biomedical Engineering (ref.1). The study showed how GI-ORIS™ can be applied to accurately model (with near-perfect predictability) the absorption of drug molecules in the small intestine, enabling Vivtex to develop novel oral formulations and delivery methodologies, previously not possible for biologic medicines based on the limitations of available technologies. Vivtex has secured a worldwide, exclusive license from MIT for this foundational technology and its applications for the development of novel oral biologic therapies.
Reference
von Erlach, T., Saxton, S., Shi, Y. et al. Robotically handled whole-tissue culture system for the screening of oral drug formulations. Nat. Biomed. Eng. 4, 544–559 (2020).
###
About Vivtex Corporation
Vivtex was launched as a spin out from the labs of Robert Langer (MIT) and Giovanni Traverso (MIT, Harvard University). The company is focused on transforming the market for biologic therapies through the development of novel oral biologics including enhanced, oral versions of existing high-value biologic candidates that can only be administered by injection or infusion.
To achieve its mission, Vivtex is leveraging its proprietary and extensively validated high-throughput GI-ORIS™ (“Gut on a chip” and AI) screening and formulation platform (Nat. Biomed. Eng. 4, 544–559: 2020) through strategic co-development partnerships and R&D collaborations with biotechnology and pharmaceutical companies.
To find out more about Vivtex, please visit our website: and LinkedIn.
Contacts:
Vivtex
Maureen Deehan, CEO
mdeehan@vivtex.com
MEDiSTRAVA Consulting (for international media)
Mark Swallow, Sandi Greenwood, Leila Adlam
Vivtex@medistrava.com
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.